New Patent Expands iBio's Bio-Defense IP Portfolio

NEWARK, Del., Oct. 3, 2012 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced issuance of a U.S. patent covering compositions of matter and methods of producing and formulating anthrax vaccines. The new patent is U.S. Patent 8,277,816 entitled "Bacillus Anthracis Antigens, Vaccine Compositions and Related Methods," and is based on an invention developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology, iBio's research collaborator.


"This new patent broadens protected uses of iBio's proprietary iBioLaunch™ platform and also expands the Company's portfolio of assets relevant to bio-defense applications, such as our successful preclinical vaccine for plague and a proprietary antibody for anthrax," said Terence Ryan, Ph.D., iBio's Chief Scientific Officer. "There should be significant interest in these opportunities from potential commercial collaborators focused on infectious disease and bio-defense markets."

Data published in peer-reviewed scientific journals previously demonstrated protection of non-human primates from anthrax spores by a proprietary antibody produced with the Company's proprietary iBioLaunch™ technology. Additional data confirmed protection of non-human primates from pneumonic plague by a proprietary vaccine incorporating iBioModulator technology produced via the iBioLaunch platform.

About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator  platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at:

Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.




Robert Erwin, President                                          

Douglas Beck, Chief Financial Officer

iBio, Inc.                                                                    

iBio, Inc.



[email protected]                                                 

[email protected]

SOURCE iBio, Inc.

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.